Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide

Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi

Clin Mol Hepatol. 2024;30(1):49-63. Published online November 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0328

View: 2467 Download: 189 Web of Science: 1 Crossref: 4

Review

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 5674 Download: 252 Web of Science: 11 Crossref: 13

Reply to Correspondence

Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B”

Pin-Nan Cheng, Ming-Lung Yu

Received April 5, 2024 Accepted April 9, 2024

DOI: https://doi.org/10.3350/cmh.2024.0228 [Epub ahead of print]

View: 496 Download: 21

1 |

Viewed By 5351	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4958	MAFLD: How is it different from NAFLD?
Viewed By 4656	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4332	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3913	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 169	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 108	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 80	MAFLD: How is it different from NAFLD?
Cited By 77	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search